Neurocrine Biosciences, Inc.

Total Valuation

Neurocrine Biosciences, Inc. carries a market capitalization of 14.26B, placing it among publicly traded companies globally. Its enterprise value stands at 17.14B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Share Statistics

Neurocrine Biosciences, Inc. currently has 101.60M shares outstanding.

Valuation Ratios

Neurocrine Biosciences, Inc. trades at a trailing price-to-earnings ratio of 23.94. The price-to-sales ratio is 5.01, and the price-to-book ratio stands at 4.64.

Enterprise Valuation

On an enterprise value basis, Neurocrine Biosciences, Inc. trades at an EV/EBITDA multiple of 20.08 and an EV/FCF ratio of 19.03. The EV/Sales ratio of 5.08 reflects the premium investors are willing to pay for the company's revenue stream, while the EV/EBIT multiple of 21.25 provides insight into valuation relative to core operating earnings.

Financial Position

Neurocrine Biosciences, Inc. maintains a current ratio of 1.87, meaning it holds 1.9x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 10.88, indicating elevated leverage, while an interest coverage ratio of 294.31 demonstrates strong ability to service its debt obligations.

Financial Efficiency

Neurocrine Biosciences, Inc. posts a return on equity of 22.09 and a return on invested capital of 16.42.

Taxes

Over the trailing twelve months, Neurocrine Biosciences, Inc. has paid 234.70M in income taxes, reflecting an effective tax rate of 24.96.

Stock Price Statistics

Neurocrine Biosciences, Inc.'s stock has declined approximately -0.71315361% over the past 52 weeks. The 50-day moving average sits at 148.73, while the 200-day moving average is 147.01.

Income Statement

Over the trailing twelve months, Neurocrine Biosciences, Inc. generated 3.37B in revenue and converted that into 705.50M in net income, yielding earnings per share of 6.82. EBITDA reached 853.50M, while operating income came in at 806.20M.

Balance Sheet

Neurocrine Biosciences, Inc. holds 389.80M in cash and equivalents against 401.80M in total debt, resulting in a net debt position of -332.40M. Total book value stands at 3.69B, with working capital of 763.00M providing operational flexibility.

Cash Flow

Neurocrine Biosciences, Inc. produced 898.10M in operating cash flow over the past twelve months.

Margins

Neurocrine Biosciences, Inc. operates with a gross margin of 97.97, reflecting its pricing power and cost economics. The operating margin of 23.90 and net profit margin of 20.91 provide insight into operational efficiency.

Dividends & Yields

Scores

Neurocrine Biosciences, Inc. posts an Altman Z-Score of 9.19, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.